tiprankstipranks
Trending News
More News >
AnaptysBio Inc (ANAB)
NASDAQ:ANAB

AnaptysBio (ANAB) AI Stock Analysis

Compare
579 Followers

Top Page

AN

AnaptysBio

(NASDAQ:ANAB)

Rating:60Neutral
Price Target:
$25.00
▲(6.88%Upside)
The overall stock score reflects a mix of strong technical momentum and promising trial results against a backdrop of financial and valuation challenges. While the technical indicators and positive trial results are encouraging, the company's current financial performance and negative valuation metrics dampen the overall score.
Positive Factors
Drug Efficacy
Rosnilimab demonstrated strong efficacy and durability across both biologic-naïve and experienced populations in rheumatoid arthritis.
Earnings
Analyst is upgrading the stock to Buy from Neutral with a price target of $38.
Investor Sentiment
Shares are up 76% year-to-date, as investors see ANAB's Jemperli royalty value as a floor for the stock and incremental data for rosnilimab continues to demonstrate a differentiated efficacy and safety profile in RA.
Negative Factors
Competitor Performance
Disappointing UC results for competitor JNJ’s PD-1 agonist JNJ-67484703 raise questions about rosnilimab’s Ph2b UC readout, although JNJ's data in RA appears weaker cross-trial relative to rosnilimab.
Ulcerative Colitis Trials
JNJ's drug appears flawed relative to rosnilimab, with discouraging results in ulcerative colitis trials.

AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)

AnaptysBio Business Overview & Revenue Model

Company DescriptionAnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company that specializes in the development of novel antibody therapies. Operating in the biopharmaceutical sector, AnaptysBio focuses primarily on the discovery and development of first-in-class immunology therapeutic antibodies aimed at treating inflammatory diseases. The company leverages its proprietary somatic hypermutation (SHM) antibody platform to generate high-affinity therapeutic antibodies against various biological targets.
How the Company Makes MoneyAnaptysBio primarily generates revenue through strategic collaborations and partnerships with larger pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and potential royalties on product sales resulting from the development and commercialization of antibody therapies. Additionally, the company may also earn revenue through licensing agreements of its proprietary technologies to other entities in the pharmaceutical industry. AnaptysBio's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the success of its collaboration agreements.

AnaptysBio Financial Statement Overview

Summary
AnaptysBio is showing strong revenue growth but continues to face significant profitability and cash flow challenges. The company remains unprofitable, with negative margins and returns. The balance sheet shows moderate leverage, but equity levels are low. Overall, the company needs to focus on enhancing profitability and cash flow to strengthen its financial position.
Income Statement
35
Negative
AnaptysBio has experienced substantial revenue growth from $10.3M in 2022 to $111.9M TTM, indicating a strong upward trajectory. However, the company continues to operate at a loss, with a negative net profit margin of -125.7% and a negative EBIT margin of -89.7% TTM. This suggests significant profitability challenges despite revenue growth.
Balance Sheet
40
Negative
The company's balance sheet shows a high debt-to-equity ratio of 0.46 TTM, indicating moderate leverage. The equity ratio stands at 8.1% TTM, reflecting a relatively low proportion of equity financing. The negative ROE of -413.2% TTM points to ongoing profitability issues impacting shareholder returns.
Cash Flow
30
Negative
AnaptysBio's free cash flow improved slightly from -$135.7M in 2024 to -$102.2M TTM, but remains negative, indicating cash flow challenges. The operating cash flow to net income ratio of 0.72 TTM shows that cash losses are closely aligned with accounting losses, highlighting limited cash flow from operations.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
111.87M91.28M17.16M10.29M63.17M75.00M
Gross Profit
110.68M88.88M14.78M7.95M-35.32M-5.03M
EBIT
-100.29M-114.95M-164.41M-115.15M-56.81M-23.88M
EBITDA
-83.27M-92.74M-143.16M-105.26M-55.71M-19.37M
Net Income Common Stockholders
-140.62M-145.23M-163.62M-128.72M-57.19M-19.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
339.94M385.37M390.90M441.24M548.10M393.65M
Total Assets
422.05M483.83M452.39M610.38M643.07M416.55M
Total Debt
15.57M16.04M17.81M19.45M20.95M342.00K
Net Debt
-83.06M-107.04M-18.15M-51.86M-474.77M-250.11M
Total Liabilities
388.03M412.97M364.29M348.28M286.64M19.82M
Stockholders Equity
34.02M70.87M88.10M262.10M356.43M396.73M
Cash FlowFree Cash Flow
-102.21M-135.69M-121.61M-73.95M-47.29M-14.73M
Operating Cash Flow
-101.84M-135.34M-120.80M-73.59M-45.92M-14.16M
Investing Cash Flow
41.63M95.40M144.75M-394.85M38.84M94.47M
Financing Cash Flow
105.16M127.05M-59.30M44.02M252.30M-879.00K

AnaptysBio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price23.39
Price Trends
50DMA
20.88
Positive
100DMA
19.09
Positive
200DMA
22.23
Positive
Market Momentum
MACD
0.88
Negative
RSI
57.54
Neutral
STOCH
81.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 23.39 is above the 20-day moving average (MA) of 22.39, above the 50-day MA of 20.88, and above the 200-day MA of 22.23, indicating a bullish trend. The MACD of 0.88 indicates Negative momentum. The RSI at 57.54 is Neutral, neither overbought nor oversold. The STOCH value of 81.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.

AnaptysBio Risk Analysis

AnaptysBio disclosed 55 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

AnaptysBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$767.67M-6.33%23.92%-27.69%
60
Neutral
$702.19M-343.83%387.20%21.00%
59
Neutral
$741.46M53.85-4.52%92.31%78.17%
55
Neutral
$754.78M-55.12%-60.26%
54
Neutral
$5.34B3.36-45.10%3.39%16.81%-0.03%
48
Neutral
$503.27M-43.77%20.38%-194.93%
46
Neutral
$376.78M-75.77%-44.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANAB
AnaptysBio
23.39
0.50
2.18%
SVRA
Savara
2.07
-1.65
-44.35%
TRVI
Trevi Therapeutics
6.07
3.43
129.92%
IMTX
Immatics
5.85
-6.58
-52.94%
PHAR
Pharming Group
10.84
2.68
32.84%
VALN
Valneva
5.72
-1.38
-19.44%

AnaptysBio Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
AnaptysBio Holds 2025 Annual Stockholders Meeting
Neutral
Jun 17, 2025

On June 17, 2025, AnaptysBio, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were adopted. These included the election of three Class II directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the approval of amendments to the company’s 2017 Equity Incentive Plan. The meeting also featured non-binding advisory votes on executive compensation and the frequency of future advisory votes concerning executive compensation. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
AnaptysBio Reports Positive Phase 2b Trial Results
Positive
Jun 3, 2025

On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis. The trial demonstrated that rosnilimab achieved JAK-like efficacy with significant improvements in disease activity and remission rates, maintaining durable responses for at least two months off drug. The findings suggest rosnilimab’s potential for extended dosing intervals and its promising impact in the $20 billion U.S. RA market.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.